"Neoplasm Staging" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Descriptor ID |
D009367
|
MeSH Number(s) |
E01.789.625
|
Concept/Terms |
Neoplasm Staging- Neoplasm Staging
- Staging, Neoplasm
- Tumor Staging
- Staging, Tumor
- Cancer Staging
- Staging, Cancer
TNM Staging- TNM Staging
- Staging, TNM
- TNM Staging System
- Staging System, TNM
- Staging Systems, TNM
- System, TNM Staging
- Systems, TNM Staging
- TNM Staging Systems
- TNM Classification
- Classification, TNM
- Classifications, TNM
- TNM Classifications
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Staging".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Staging".
This graph shows the total number of publications written about "Neoplasm Staging" by people in this website by year, and whether "Neoplasm Staging" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 7 | 7 |
1996 | 0 | 7 | 7 |
1997 | 0 | 10 | 10 |
1998 | 0 | 12 | 12 |
1999 | 0 | 9 | 9 |
2000 | 2 | 9 | 11 |
2001 | 2 | 15 | 17 |
2002 | 2 | 11 | 13 |
2003 | 1 | 32 | 33 |
2004 | 1 | 21 | 22 |
2005 | 2 | 29 | 31 |
2006 | 1 | 25 | 26 |
2007 | 1 | 33 | 34 |
2008 | 2 | 46 | 48 |
2009 | 2 | 37 | 39 |
2010 | 0 | 42 | 42 |
2011 | 2 | 48 | 50 |
2012 | 3 | 44 | 47 |
2013 | 3 | 46 | 49 |
2014 | 2 | 43 | 45 |
2015 | 2 | 54 | 56 |
2016 | 4 | 45 | 49 |
2017 | 5 | 58 | 63 |
2018 | 1 | 39 | 40 |
2019 | 5 | 48 | 53 |
2020 | 3 | 35 | 38 |
2021 | 3 | 30 | 33 |
2022 | 0 | 18 | 18 |
2023 | 2 | 13 | 15 |
2024 | 7 | 10 | 17 |
2025 | 1 | 10 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Staging" by people in Profiles.
-
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer. Clin Cancer Res. 2025 May 01; 31(9):1615-1624.
-
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial. Breast Cancer Res Treat. 2025 Jul; 212(1):57-69.
-
Transcriptomic signatures in peripheral CD4+T-lymphocytes may reflect melanoma staging and immunotherapy responsiveness prior to ICI initiation. Front Immunol. 2025; 16:1529707.
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025 May 02; 220:115381.
-
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76?K trial. Eur J Cancer. 2025 May 02; 220:115371.
-
Optimizing Outcomes in Gallbladder Cancer: Identifying Predictors of Futile Up-Front Surgery in a Global Multi-center Study. Ann Surg Oncol. 2025 Jun; 32(6):4374-4382.
-
The Diagnostic Role of the Platelet-to-Lymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2025 Feb 21; 26(5).
-
Survival Outcomes Between Minimally Invasive and Open Gastrectomy in Early and Locally Advanced Gastric Adenocarcinoma in a Western Center. J Gastrointest Cancer. 2025 Feb 20; 56(1):68.
-
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2025 Feb 03; 31(3):529-542.
-
Lymph Node Staging and Treatment in Pediatric Patients With Soft Tissue Sarcomas: A Consensus Opinion From the Children's Oncology Group, European paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer. 2025 Apr; 72(4):e31538.